By contrast, administration of the allosteric GPR43 agonist to allogeneic Gpr43−/− B6 animals did not mitigate GVHD (Fig. 3c, d), demonstrating the specificity of GPR43 in mitigating GVHD. Here, FFAR2 is linked to graft versus host disease.